Study about efficacy and tolerance of acetate free biofiltration (AFB) in dialysis patients:clinical significance of acetate free and acidisis correction.(NABI study:Nagoya acetate free biofiltration study)

Study about efficacy and tolerance of acetate free biofiltration (AFB) in dialysis patients:clinical significance of acetate free and acidisis correction.(NABI study:Nagoya acetate free biofiltration study) - NABI study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000827

Enrollment

Registered

2007-09-28

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysdialysis syndrome

Interventions

1)A:from HDF to AFB 2) B:from AFB to HDF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)written informed consent and dysdialysis syndrom. (2)receive hemodialysis 3 times a week (3)Iron is controlled enough.(TSAT 20%)

Exclusion criteria

Exclusion criteria: (1)blood disease, malignant disorder, severe liver disorder (2) uses steroid, immunosuppression agent (3) 20 years or older. (4) participating in another clinical trial for 12 weeks or longer. (5) pregnant, during the nursing, possibly pregnant and having the hope of child bearing. (6)judged inappropriate as study subject by the investigator.

Design outcomes

Primary

Measure	Time frame
Ffficacy (1)circulation stability (Blood pressure,PWV) (2)improvement of QOL (3)clinical significance of acidosis correction (Ca and Pi metabolism) (4)clinical significance of Acetate free (endthelial injury,inflammation)	—

Countries

Japan

Contacts

Public ContactYoshiki Morita

Nagoya University Nephrology

052-744-2192

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026